These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25018638)

  • 1. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
    Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
    Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
    Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
    Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
    Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
    Noguchi K; Ikawa Y
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
    Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
    Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
    Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
    J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma.
    Tian C; Zhang Y
    Onco Targets Ther; 2016; 9():5659-5661. PubMed ID: 27695344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
    Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.